231 related articles for article (PubMed ID: 33488103)
1. Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.
Yeo S; Holl K; Peñaherrera N; Wissinger U; Anstee K; Wyn R
Clinicoecon Outcomes Res; 2021; 13():31-38. PubMed ID: 33488103
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and mortality in men: Role of androgens.
Fallara G; Pozzi E; Corsini C; Belladelli F; Boeri L; Capogrosso P; Montorsi F; Salonia A
Best Pract Res Clin Endocrinol Metab; 2022 Jul; 36(4):101662. PubMed ID: 35484028
[TBL] [Abstract][Full Text] [Related]
3. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
4. Major cardiovascular disease risk in men with testosterone deficiency (hypogonadism): appraisal of short, medium and long-term testosterone therapy - a narrative review.
Traish AM
Sex Med Rev; 2023 Sep; 11(4):384-394. PubMed ID: 37587664
[TBL] [Abstract][Full Text] [Related]
5. A practical guide to male hypogonadism in the primary care setting.
Dandona P; Rosenberg MT
Int J Clin Pract; 2010 May; 64(6):682-96. PubMed ID: 20518947
[TBL] [Abstract][Full Text] [Related]
6. Male-specific consequences of obesity - functional hypogonadism and fertility disorders.
Rabijewski M
Endokrynol Pol; 2023; 74(5):480-489. PubMed ID: 37779374
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
8. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
9. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
10. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism.
Almehmadi Y; Yassin DJ; Yassin AA
Aging Male; 2015; 18(3):186-94. PubMed ID: 26030350
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk?
Afiadata A; Ellsworth P
Hosp Pract (1995); 2014 Dec; 42(5):69-82. PubMed ID: 25485919
[TBL] [Abstract][Full Text] [Related]
12. Sperm Count and Hypogonadism as Markers of General Male Health.
Ferlin A; Garolla A; Ghezzi M; Selice R; Palego P; Caretta N; Di Mambro A; Valente U; De Rocco Ponce M; Dipresa S; Sartori L; Plebani M; Foresta C
Eur Urol Focus; 2021 Jan; 7(1):205-213. PubMed ID: 31427194
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.
Traish AM; Haider A; Haider KS; Doros G; Saad F
J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):414-433. PubMed ID: 28421834
[TBL] [Abstract][Full Text] [Related]
14. Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined?
Traish AM
Am J Physiol Regul Integr Comp Physiol; 2016 Sep; 311(3):R566-73. PubMed ID: 27488887
[TBL] [Abstract][Full Text] [Related]
15. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Yassin AA; Nettleship JE; Salman M; Almehmadi Y
Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population.
Grabner M; Bodhani A; Khandelwal N; Palli S; Bonine N; Khera M
J Sex Med; 2017 Jan; 14(1):88-97. PubMed ID: 27939338
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
Hackett G
Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
[TBL] [Abstract][Full Text] [Related]
19. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
